Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
Name
ciab913.pdf
Description
Published version
Size
769.37 KB
Format
Adobe PDF
Checksum (MD5)
5c0e113fbdfc1cf9fad9dc7930c072c8
Author(s)
Weld, Ethel D
Astemborski, Jacqueline
Kirk, Gregory D
Sulkowski, Mark S
Katz, Stephanie
Rothman, Richard
Solomon, Sunil S
Matthews, Gail V
Hsieh, Yu Hsiang
Verma, Malvika
Date Issued
October 26, 2021
Journal
Clinical Infectious Diseases
Publisher
Oxford University Press
Citation
thel D Weld, Jacqueline Astemborski, Gregory D Kirk, Mark S Sulkowski, Stephanie Katz, Richard Rothman, Sunil S Solomon, Gail V Matthews, Yu Hsiang Hsieh, Malvika Verma, Giovanni Traverso, Susan Swindells, Andrew Owen, Jordan Feld, Charles Flexner, Shruti H Mehta, David L Thomas, Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments, Clinical Infectious Diseases, Volume 75, Issue 1, 1 July 2022, Pages 3–10.
Version
Final published version
Abstract
Background
Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment.
Methods
A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills.
Results
Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1–3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future.
Conclusions
These data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1093/cid/ciab913
